Cytokinetics

YTD

ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.

CEO

Robert I. Blum

CEORobert I. Blum

Employees

673

Employees673

Headquarters

South San Francisco, California

HeadquartersSouth San Francisco, California

Founded

1997

Founded1997

Employees

673

Employees673

CYTK Key Statistics

Market cap

10.68B

Market cap10.68B

Price-Earnings ratio

-10.64

Price-Earnings ratio-10.64

Dividend yield

—

Dividend yield—

Average volume

1.70M

Average volume1.70M

High today

$77.68

High today$77.68

Low today

$76.65

Low today$76.65

Open price

$77.30

Open price$77.30

Volume

1.52M

Volume1.52M

52 Week high

$88.31

52 Week high$88.31

52 Week low

$35.22

52 Week low$35.22

Stock Snapshot

With a market cap of 10.68B, Cytokinetics(CYTK) trades at $76.88. The stock has a price-to-earnings ratio of -10.64.

During the trading session on 2026-08-22, Cytokinetics(CYTK) shares reached a daily high of $77.68 and a low of $76.65. At a current price of $76.88, the stock is +0.3% higher than the low and still -1.0% under the high.

Trading activity shows a volume of 1.52M, compared to an average daily volume of 1.7M.

Over the past 52 weeks, Cytokinetics(CYTK) stock has traded between a high of $88.31 and a low of $35.22.

CYTK News

Zacks 3d

Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock? - Zacks Investment Research

...

TipRanks 3d

Top Cytokinetics Executive Makes Attention-Grabbing Move With Insider Stock Sale

New insider activity at Cytokinetics ( (CYTK) ) has taken place on August 18, 2026. Summer Sale - Claim 70% Off TipRanks Unlock powerful investing tools with Ti...

TipRanks 4d

Cytokinetics Earnings Call Highlights MYQORZO Surge

Cytokinetics ((CYTK)) has held its Q2 earnings call. Read on for the main highlights of the call. Summer Sale - Claim 70% Off TipRanks Unlock powerful investing...

Analyst ratings

91%

of 23 ratings

Buy

91.3%

Hold

8.7%

Sell

More CYTK News

Simply Wall St 7d

Will MYQORZO Traction Amid Weaker Q2 2026 Results Change Cytokinetics' Narrative

Cytokinetics, Incorporated previously reported second-quarter 2026 results showing revenue of US$28.62 million versus US$66.77 million a year earlier, alongside...

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.